NCT06481085: An ongoing trial by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
This trial is ongoing. It must report results 8 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06481085 |
|---|---|
| Title | A Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of HDM1002 Tablets in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin or Diet and Exercise |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 27, 2024 |
| Completion date | May 30, 2025 |
| Required reporting date | May 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Sept. 11, 2025 |
| Days late | None |